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Age specific trends in asthma mortality in England and
Wales, 1983›95: results of an observational study
M J Campbell, G R Cogman, S T Holgate, S L Johnston
Abstract
Objective: To determine trends in asthma mortality
by age group in England and Wales during 1983›95.
Design: Observational study.
Setting: England and Wales.
Subjects: All deaths classified as having an underlying
cause of asthma registered from 1 January 1983 to
31 December 1995.
Main outcome measure: Time trends for age specific
asthma deaths.
Results: Deaths in the age group 5›14 years showed
an irregular downward trend during 1983›95; deaths
in the age groups 15›44, 45›64, and 65›74 years
peaked before 1989 and then showed a downward
trend; and deaths in the age group 75›84 years
peaked between 1988 and 1993 and subsequently
dropped. Trends were: age group 5›14 years, 6% (95%
confidence interval 3% to 9%); 15›44 years, 6%
(5% to 7%); 45›64 years, 5% (4% to 6%); 65›74 years,
2% (1% to 3%). Deaths in the 75›84 and 85 and over
categories plateaued.
Conclusions: There are downward trends in asthma
mortality in Britain, which may be due to increased
use of prophylactic treatment.
Introduction
It is now over 10 years since trends and seasonality in
asthma mortality were investigated in England and
Wales,1›3 and the long term trends over the period
1974›84 were found to be increasing. We aimed at
updating these findings in the light of changing views
on the appropriateness of treatment for asthma,
increasing concerns in relation to environmental
effects on asthma, and also concerns on admission
rates for asthma.4
Method
The data were obtained from the Office of Population
Censuses and Surveys (now the Office for National
Statistics). They consisted of all deaths classified as hav›
ing an underlying cause of asthma (International
Classification of Diseases, ninth revision (ICD›9), codes
493.0 to 493.9 inclusive) registered in England and
Wales from 1 January 1983 to 31 December 1995.
Some coding procedures were changed in 1983, so the
data were analysed including and excluding that year
to see if the change affected conclusions. Data included
the date of death, cause of death, sex of subject, and age
at death. Annual age specific population sizes and
death rates for all respiratory deaths (ICD›9 codes
460›519) were obtained from Office of Population
Censuses and Surveys publications.
For analysis the data were split into seven age
groups, coinciding with the Office of Population
Censuses and Surveys age classifications 0›4, 5›14,
15›44, 45›64, 65›74, 75›84, and 85 years and over. The
number of people alive during each year in these age
groups was obtained from census projections. Deaths
were aggregated into years. The appendix describes
the method of analysis.
Results
In total, 23 311 asthma deaths were registered between
1 January 1983 and 31 December 1995. The
proportions of these deaths in each age group 0›4,
5›14, 15›44, 45›64, 65›74, 75›84, and 85 and over were
0.5%, 1%, 12%, 27%, 26%, 24%, and 10% respectively.
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Fig 1 Death rates from asthma per million population by age group
from 1983 to 1995
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Figure 1 shows the yearly asthma death rates plot›
ted on a log scale for each age group. Table 1 gives the
results of the Poisson analysis. Little could be made of
the data for the under 5s because the numbers were
too small. For all age groups except 5›14 there was a
significant quadratic term. For each age group between
15 and 74 both linear and quadratic terms were nega›
tive, implying an accelerating decline which started
before 1989. For subjects aged 75›84 the linear term
was positive, suggesting that mortality initially rose and
then either peaked or plateaued after 1989. Visual
inspection of the data suggests that for those aged
75›84 there was a drop in 1994 and 1995, but for those
aged 85 and over no decline was evident.
Excluding 1983 made little difference to the results.
As the model was on a log scale, disregarding the
quadratic term we can interpret the linear coefficients
as a proportionate drop. Hence for deaths between 5
and 14 years of age the drop was about 6% a year (95%
confidence interval 3% to 9% ), for deaths at ages
15›44 years it was also 6% (5% to 7%), for deaths
at ages 45›64 years it was 5% (4% to 6%), and for deaths
at ages 65›74 years it was 2% (1% to 3%). For deaths
in subjects aged 75 and over the rate was flat.
Total respiratory deaths also decreased after about
1991 in subjects aged 5›14 and 15›44. In 1991 as a
proportion of all respiratory deaths asthma deaths
accounted for 44% among subjects aged 5›14 years,
31% among those aged 15›44, 11% among those aged
45›64, and 2% among those over 65.
Discussion
In contrast with studies up to the mid›1980s1›3 which
showed increasing mortality, we have shown that since
the late 1980s asthma mortality in England and Wales
seems to have dropped except among people aged
over 85. Other countries have had different experi›
ences. In Scotland mortality was stable between 1975
and 1989 for 5›44 year olds.5 In France a peak in
mortality for both the under 35s and over 35s was
observed from 1985 to 1987; this was attributed to
influenza epidemics, and though death rates were
lower subsequently there was no evidence of a trend.6
In contrast, deaths in New Zealand at ages 5›54 years
showed a downward trend from 1986 to 1992.7
Trends in asthma mortality among children are
reflected in the trends in asthma admissions to
hospital. Routine data for asthma admissions are not
available for England after 1985, but for Wales admis›
sions showed a steady rise from 1983 to 1988 and then
a drop in 1989 and 1990.4 Age standardised death
rates seem to reflect this trend.
There has been considerable concern in the medical
community and in the public domain over reports of
increasing asthma prevalence.8 It is encouraging to note
that even with a background of increasing prevalence
there were downward trends in mortality in the under
75s in the five to seven years before 1995. It is possible
that these trends were a result of increased awareness
among physicians and patients of the inflammatory
basis of asthma and the need for prophylactic treatment,
particularly in view of the increased prescribing of corti›
costeroids as a proportion of all prescriptions for
asthma.9 Diagnostic transfer is a possibility, but it is reas›
suring that respiratory deaths are also dropping in
younger people. The accuracy of death certification in
asthma was not good in 1979 but has been shown to be
more accurate for younger people.10 In old people
asthma deaths form only a small proportion of all respi›
ratory deaths and it would be impossible to quantify the
extent of diagnostic transfer.
The trends in asthma mortality may be related to
the increased use of prophylactic treatment, the use of
which should continue to be encouraged.
We thank the Office for National Statistics (formerly the Office
of Population Censuses and Surveys) for the data and Mr S A
Julious for additional references.
Funding: None.
Conflict of interest: None.
Appendix
Analysis was by Poisson regression in STATA.11 The
midyear population was included as an “offset,” which
ensured the analysis was based on a rate and allowed for
changes in the age structure of the population. Checks
for overdispersion and serial correlation of the residuals
were carried out but it was not found necessary to make
allowances for them. Trend terms were centred on the
midyear 1989. When the linear and quadratic terms
were negative this implied that the fitted model peaked
before 1989. When the linear term was positive and the
quadratic term was negative this implied that the model
had peaked or plateaued or was expected to peak or
plateau after 1989. When both coefficients were positive
an increasing and accelerating rate was implied.
1 Khot A, Burn R. Seasonal variation and time trends of deaths from
asthma in England and Wales 1960›82. BMJ 1984;289:233›4.
2 Burney PGJ. Asthma mortality in England and Wales: evidence for a fur›
ther increase, 1974›84. Lancet 1986;ii:323›6.
Table 1 Trends in asthma mortality 1983›95
Age group
(years)
No of
deaths
Linear and
quadratic
coefficients Estimate† SE P value
5›14 277 Time −0.0593 0.0164 0.001
Time2 0.0005 0.0049 0.914
15›44 2874 Time −0.0598 0.0054 <0.001
Time2 −0.0091 0.0016 <0.001
45›64 6185 Time −0.0489 0.0036 <0.001
Time2 −0.0071 0.0011 <0.001
65›74 6005 Time −0.0190 0.0036 <0.001
Time2 −0.0062 0.0011 <0.001
75›84 5717 Time 0.0038 0.0037 0.31
Time2 −0.0065 0.0011 <0.001
>85 2253 Time 0.0311 0.0062 <0.001
Time2 −0.0076 0.0018 <0.001
†Coefficient from Poisson regression for annual asthma deaths.
Key messages
x Asthma mortality in England and Wales is
dropping by about 6% a year in people aged
5›64 years
+ It is changing only slowly in those aged 65 and
over
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ing asthma mortality in Scotland. Scott Med J 1992;37:5›7.
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seasonal variation and peaking of mortality in 1985›87. Rev Epidemiol
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7 Garrett J, Kolle J, Richards G, Whitelock T, Rae H. Major reduction in
asthma morbidity and continued reduction in mortality in New Zealand.
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9 Baldwin DR, Ormerod LP, Mackay AD, Stableforth DE. Change in hos›
pital management of acute severe asthma by general and thoracic physi›
cians in Birmingham and Manchester during 1978 and 1985. Thorax
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10 BTA Research Committee. Accuracy of death certificates in bronchial
asthma. Thorax 1984;39:505›9.
11 StatCorp. Stata statistical software: release 5.0. College Station, Texas: Stata
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Effect of long term treatment with salmeterol on asthma
control: a double blind, randomised crossover study
Paul Wilding, Miranda Clark, Joanna Thompson Coon, Sarah Lewis, Lesley Rushton, Jon Bennett,
Janet Oborne, Susan Cooper, Anne E Tattersfield
Abstract
Objectives: To determine the effect of adding
salmeterol 50 ìg twice daily for six months to current
treatment in subjects with asthma who control their
inhaled corticosteroid dose according to a
management plan.
Design: A double blind, randomised crossover study.
Setting: Nottingham.
Subjects: 101 subjects with mild or moderate asthma
taking at least 200 ìg twice daily of beclomethasone
dipropionate or budesonide.
Interventions: Salmeterol 50 ìg twice daily and
placebo for six months each, with a one month
washout. Subjects adjusted inhaled steroid dose
according to guidelines.
Main outcome measure: Reduction in inhaled
steroid use, exacerbations of asthma, and use of oral
steroids.
Results: Data were available for 87 subjects. When
compared with placebo salmeterol treatment was
associated with a 17% reduction in inhaled steroid use
(95% confidence interval 12% to 22%) with no
significant difference in the number of subjects who
had an exacerbation (placebo 25%, salmeterol 16%)
or use of oral steroids. For secondary end points
salmeterol treatment was associated with higher
morning and evening peak expiratory flow and forced
expiratory volume in one second; a reduction in
symptoms, bronchodilator use, and airway
responsiveness to methacholine; and no effect on
serum potassium concentration, 24 hour heart rate, or
the final forced expiratory volume in one second
achieved during a salbutamol dose›response study.
Conclusions: In subjects who adjusted their inhaled
steroid treatment according to guidelines the addition
of salmeterol 50 ìg twice daily was associated with a
reduction in inhaled steroid use and improved lung
function and symptom control.
Introduction
Salmeterol, a long acting â2 agonist, when inhaled
twice daily, causes bronchodilatation that is maintained
over 24 hours.1 2 The findings by Sears et al that asthma
control was worse when subjects took the short acting
â2 agonist fenoterol regularly rather than a â2 agonist
as required3 led to concerns that regular treatment with
long acting â2 agonists might have similar adverse
effects. Subsequent studies comparing salmeterol 50 ìg
twice daily with placebo have shown that salmeterol
causes bronchodilatation that is maintained for at least
three months4 5 and an improvement in quality of life6
and symptom control.4›9 When compared with placebo
or salbutamol, however, salmeterol has usually not
reduced exacerbations,4 5 8›11 nor does it reduce inflam›
mation in asthmatic airways.12 13
Current recommendations suggest that treatment
for asthma should be modified according to symptoms
and peak expiratory flow measurements.14 15 The intro›
duction of a long acting â2 agonist may therefore lead
to a reduction in inhaled corticosteroid use. Previous
studies have looked at the effect of adding salmeterol
when inhaled steroid dose is kept constant. We
determined the effect of adding salmeterol to other
treatment on the basis of current practice, with subjects
changing their inhaled steroid dose according to
predetermined criteria based on symptoms and peak
expiratory flow. We studied the long term efficacy and
safety of salmeterol in subjects with mild or moderate
asthma who took salmeterol and placebo for six
months each.
Methods
Subjects
We recruited 101 subjects (50 female) aged 19›60 years
from our register of asthma volunteers and from
outpatient clinics in Nottingham and Mansfield. The
subjects had to have a forced expiratory volume in one
second of at least 50% predicted and either (a) a 15%
increase in forced expiratory volume in one second
after inhaling salbutamol 400 ìg at entry or within a
year or (b) 15% diurnal variability in peak expiratory
flow recordings. All were receiving an inhaled short
acting â2 agonist as needed and at least 400 ìg/day
beclomethasone dipropionate or budesonide. Two
subjects were taking ipratropium bromide and two
theophylline, both in constant dose throughout the
study. All had stable asthma at entry, with no exacerba›
tions or respiratory tract infection in the previous six
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weeks. Subjects gave written informed consent; the
study was approved by Nottingham City Hospital’s
ethics committee.
Measurements
We measured forced expiratory volume in one second
and forced vital capacity with a dry bellows spirometer,
the Vitalograph (Vitalograph, Buckingham), as the best
of three readings within 100 ml for forced expiratory
volume in one second. We measured peak expiratory
flow with a mini›Wright peak flow meter (Clement
Clarke, Harlow) as the best of three readings. A
salbutamol dose›response curve was obtained by the
patient inhaling salbutamol at 15 minute intervals to
provide cumulative doses of 100 ìg, 200 ìg, 400 ìg,
and 800 ìg. We measured bronchial reactivity using a
modified method of Yan et al,16 with the subjects inhal›
ing three puffs of saline followed by doubling doses of
methacholine from 0.048 ìmol to 196 ìmol. We meas›
ured forced expiratory volume in one second one
minute after each dose, and the test was stopped when
it had fallen by at least 20%. The provocative dose of
methacholine causing a 20% fall in forced expiratory
volume in one second (PD20) was calculated by linear
interpolation of the last two readings on the log dose›
response plot. The subjects took no study drugs within
eight hours, no short acting â2 agonists within four
hours, and no ipratropium bromide within 24 hours of
all visits.
The subjects recorded peak expiratory flow before
taking the study drug, rescue bronchodilator use, and
day and night›time symptom scores (0 = no symptoms,
4 or 5 = severe symptoms) twice daily throughout
the study.
Protocol
This was a double blind, crossover study in which the
subjects inhaled placebo and salmeterol 50 ìg twice
daily from identical dry powder inhalers (Diskhaler
with Rotadisk; GlaxoWellcome, Greenford) for 24
weeks followed by a four week washout, the order of
treatment being randomised by computer program.
We assessed asthma control after a two week run›in
when the subjects recorded peak expiratory flow and
symptom scores. If control was considered reasonable
by both the doctor and the subject an individualised
“target” peak expiratory flow representing good
control of asthma was determined and the subject
issued with a personalised management plan (see
below). Otherwise the steroid dose was increased or
reduced by one puff twice daily with further review
after four weeks, or for longer if necessary, until their
asthma was stable. One puff could be 100 ìg, 200 ìg,
250 ìg, or 400 ìg of beclomethasone dipropionate or
budesonide according to the inhaler used (which was
constant throughout the study). The subjects requiring
less than 200 ìg beclomethasone dipropionate or
budesonide twice daily were excluded from entry.
We measured forced expiratory volume in one sec›
ond and forced vital capacity every four weeks during
the 56 week study and determined the number of used
and unused Rotadisks to assess compliance. We meas›
ured PD20 methacholine and serum potassium
concentration after 12 and 24 weeks of each treatment,
carried out a salbutamol dose›response study at 20
weeks (both at least 8 hours after study treatment), and
performed 24 hour electrocardiography by Holter
monitor during weeks 1 and 24. A 24 hour contact
telephone number and physician with a radiopager
were available throughout the study.
Asthma management plan
We adjusted treatment at clinic visits and between visits
with written and oral instruction, which was reinforced
at each visit. When the subjects had had no symptoms
and a morning peak expiratory flow greater than or
equal to their target peak expiratory flow for 14
consecutive days they reduced their inhaled steroid
dose by one puff twice daily; they were not allowed,
however, to reduce the dose by more than one puff
twice daily below the dose at entry. If morning or
evening peak expiratory flow fell by 10% on two
consecutive days or by 15% on one day subjects
increased their inhaled steroid by two puffs twice daily
for at least one week, adding 30 mg prednisolone daily
if peak expiratory flow fell by 30%. The additional
treatment was continued until symptom scores and
peak expiratory flow had returned to previous levels,
when it was reduced by one puff twice daily per week to
the previous dose or by 5 mg prednisolone every two
days; if a subject’s condition deteriorated the higher
dose was maintained.
Exacerbations were defined by the presence of any
two of the following: a 30% fall in morning peak
expiratory flow from target peak expiratory flow; a fall
in forced expiratory volume in one second of either 0.7
litres or 30% from baseline; increased use of â2 agonist
(by more than four puffs a day); the need for oral pred›
nisolone; more treatment on two consecutive nights or
increased symptom scores on two successive days.
Analysis
Primary end points were mean daily inhaled steroid
dose, number of exacerbations, and courses of oral
prednisolone over the last five months of treatment.
Parametric analyses were performed on mean values
of forced expiratory volume in one second; morning
and evening peak expiratory flow; minimum, mean,
and maximum heart rate; and log transformed values
for daily inhaled steroid dose, serum potassium
concentrations, and PD20 methacholine. PD20 values
were included only if measured within 8›14 hours of
the study drug (66% of subjects). Reversibility to
salbutamol was characterised by mean initial and
maximum forced expiratory volume in one second
and mean increase in forced expiratory volume in one
second. For end points measured over the last five
months of treatment, all the subjects with data for at
least one day of treatment were included in the analy›
ses. Initially, an analysis of variance model was fitted
containing terms for the main effects of baseline (mean
over last two weeks of the run›in when appropriate),
treatment, period, carry over, subject within sequence
(order of drug randomisation), and a baseline by treat›
ment interaction.17 The effects of baseline, carry over,
and interactions were removed if non›significant at the
10% level; the main model then fitted included terms
for subject, period, and treatment only.
All remaining outcomes including the percentage
of days (24 hours) without use of a bronchodilator and
symptom free days and nights were analysed
non›parametrically by Wilcoxon’s rank sum test to
Papers
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establish the significance of treatment and carry over
effects. Differences in numbers of exacerbations and
courses of oral steroids were compared with Prescott’s
test.17
Results
Of the 101 subjects who entered the study, 14 subjects
failed to complete the study owing to protocol
violations (three), pregnancy (three), personal reasons
(five), and adverse events (three; see results). Data for
the efficacy analysis were available for 87 subjects,
including one subject who moved house during month
10. Mean compliance was 92%, with 67% and 64% of
subjects achieving more than 90% compliance with
placebo and salmeterol respectively.
Subjects consisted of 51 men and 50 women with a
mean age of 39 (SD 10) years; 50 had never smoked, 39
were former smokers, and 12 were current smokers.
Most of the 101 subjects had a positive skin test to
house dust mite (71%), cat (79%), or grass pollen (56%).
Table 1 shows the subjects’ lung function.
Baseline measurements of subjects were similar
regardless of which drug they had been randomised to
receive first—salmeterol (n = 51) or placebo (n = 50)
(table 1). There were no carry over effects (all P > 0.15)
apart from minimum heart rate (P = 0.09), which was
excluded from further analysis. The only significant
interaction between treatment and baseline measure›
ments was a weak interaction with baseline inhaled
steroid dose (P = 0.10).
Primary end points
Geometric mean inhaled steroid use was stable over
the last five months of each treatment (fig 1) and
significantly lower with salmeterol (561 ìg) than with
placebo (674 ìg); the average difference was 17% (95%
confidence interval 12% to 22%, P < 0.001). Analysis
according to baseline inhaled steroid dose showed that
the 45 subjects initially taking 600 ìg or less had a 19%
lower inhaled steroid dose with salmeterol (329 ìg)
than with placebo (404 ìg) (12% to 25%), whereas the
42 subjects taking more than 600 ìg inhaled steroid
initially showed a 14% difference (6% to 21%; 998 ìg v
1162 ìg inhaled steroid).
Most subjects had no exacerbation (n = 52) and
needed no oral steroids (n = 66) during the study, and
most of the remaining subjects had one exacerbation
or one course of oral steroids only (table 2). Oral ster›
oids were used more often in the first six months than
the second six months with both placebo (8 v 5
subjects) and salmeterol (7 v 2).
With salmeterol and placebo 16 and 25 subjects
respectively had an exacerbation, and 9 and 13 subjects
had a course of oral steroids; neither difference was
significant. Most (27/34) of the episodes in which sub›
jects took oral steroids fulfilled the criteria for an exac›
erbation; some exacerbations were not treated with
oral steroids.
Secondary endpoints
Lung function and bronchial responsiveness
Table 3 and figure 2 show that salmeterol was
associated with higher peak expiratory flow values
compared with placebo in both the morning and
evening and that forced expiratory volume in one sec›
ond and forced vital capacity were also significantly
higher with salmeterol.
Geometric mean values for PD20 methacholine
were significantly higher after salmeterol than placebo
(table 3). The salbutamol dose›response study showed
a higher initial forced expiratory volume in one second
(2.82 v 2.71 litres, P < 0.001) and a smaller increase in
Table 1 Baseline characteristics of subjects receiving salmeterol first (sequence 1) and
placebo first (sequence 2) and of all subjects combined
Sequence 1
(n=51)
Sequence 2
(n=49*)
All subjects
(n=100†)
Mean (SD) forced expiratory volume in one
second (l)
2.74 (0.82) 2.69 (0.75) 2.71 (0.79)[80‡]
Mean (SD) peak expiratory flow (l/min):
Morning 415 (97) 415 (106) 415 (101)[80‡]
Evening 439 (95) 423 (102) 431 (98)[83‡]
Geometric mean (range) daily dose inhaled
steroid (ìg)
701 (400›2000) 721 (400›3000) 711 (400›3000)
Median (range) symptom score:
Day 0.5 (0›3) 0 (0›3) 0 (0›3)
Night 0 (0›2) 0 (0›2.5) 0 (0›2.5)
Median % (range) of symptom free days 50 (0›100) 62 (0›100) 56 (0›100)
Median % (range) of symptom free nights 85 (0›100) 100 (0›100) 93 (0›100)
Median (range) bronchodilator use (puffs/day) 3 (0›11) 2 (0›14) 2.5 (0›14)
Median % (range) of bronchodilator free days 7 (0›100) 14 (0›100) 8 (0›100)
*n=50 for forced expiratory volume in one second.
†n=101 for forced expiratory volume in one second.
‡Percentage predicted.
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Fig 1 Geometric mean inhaled steroid dose during treatment with
salmeterol and placebo, with standard error bars
Table 2 Oral steroid use and asthma exacerbations during last
five months of treatment with placebo and salmeterol
No of subjects
Placebo Salmeterol
No of discrete courses of steroids:
None 74 78
1 7 7
2 5 1
3 0 0
4 1 1
No of asthma exacerbations:
None 62 71
1 20 13
2 2 2
3 1 1
>3 2 0
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forced expiratory volume in one second (11% v 16%)
during the salmeterol treatment period compared with
placebo, but the maximum forced expiratory volume
in one second achieved was almost identical (3.11 v
3.10 litres, P = 0.68) (fig 3).
Symptom scores and use of bronchodilator
The subjects had more symptom free days and nights
and used less relief bronchodilation with salmeterol.
The median percentages for salmeterol and placebo
were 96% and 86% for symptom free nights, 82% and
64% for symptom free days, and 73% and 58% for
bronchodilator free days (all differences significant at
P < 0.001).
Safety aspects
Serum potassium concentrations with salmeterol and
placebo did not differ significantly (table 3). The quality
of the 24 hour electrocardiography on all four occasions
was sufficient to be able to assess maximum heart rate in
60 subjects and mean heart rate in 47. There were no
significant differences in mean or maximum 24 hour
heart rate between placebo and salmeterol (table 3) and
no difference in the frequency distribution of ventricular
and supraventricular ectopic beats.
Three subjects withdrew from the study because of
adverse events, two during or after salmeterol
treatment (chest pain and hair loss), and one during
placebo (headache).
Salmeterol was associated with more palpitations
(4 v 1); other expected adverse effects occurred
infrequently with placebo (cramp 2, hypokalaemia 1,
tremor 1) but not with salmeterol treatment.
Discussion
Long term regular treatment with the short acting â2
agonists has provided no perceptible clinical benefit in
most studies.3›6 18 19 Concern that they may have delete›
rious effects emphasised the need for long term studies
of the long acting â2 agonists.
3 Recent studies suggest
that when added to other treatment the long acting â2
agonists improve asthma control compared with
placebo4›11 and salbutamol.4›6 Our study design differed
from previous studies in that the subjects were asked to
adjust their inhaled steroid intake within certain limits
according to their peak flow rate and symptoms. This
design was chosen to ensure that subjects were not
undertreated or overtreated with steroids for a long
period and to mimic what is likely to happen in clinical
practice when salmeterol is introduced.14 15 The
subjects were taking different types and different
strengths of steroid inhaler, but these remained
constant for an individual throughout the study.
Table 3 Mean values for secondary end points after placebo and salmeterol
Salmeterol Placebo Difference (95% CI) Significance
Forced expiratory volume in
one second (l)
2.84 2.71 0.13 (0.085 to 0.174) P<0.001
Forced vital capacity (l) 4.01 3.89 0.12 (0.058 to 0.179) P<0.001
Peak expiratory flow (l/min):
Morning 451 431 19 (14 to 24) P<0.001
Evening 456 440 16 (11 to 22) P<0.001
PD20 methacholine* (ìmol):
3 Months 3.20 2.26 0.5 (0.03 to 0.99)† P=0.04
6 Months 2.24 1.46 0.62 (0.18 to 1.05)† P=0.008
Heart rate (beats/min):
Mean:
Week 1 77 75 1 (0 to 3) P=0.1
Week 24 78 77 1 (−1 to 3) P=0.3
Maximum:
Week 1 131 135 −3 (−8 to 1) P=0.1
Week 24 133 129 4 (−1 to 8) P=0.1
Serum potassium (mmol/l):
3 Months 4.00 3.94 1.02 (0.99 to 1.04)‡ P=0.1
6 Months 3.99 3.92 1.02 (0.99 to 1.05)‡ P=0.3
Mean values for forced expiratory volume in one second and forced vital capacity are for the last five
months of treatment; those for PD20 methacholine and serum potassium concentration are geometric
means.
*Provocative dose causing a 20% fall in forced expiratory volume in one second.
†Difference in doubling doses.
‡Antilogged differences in serum potassium concentration are expressed as a ratio.
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The subjects followed their management plan well,
and the relatively low incidence of exacerbations
suggests that it was effective.
By basing the study on a single centre we aimed to
ensure high compliance with treatment and a low
withdrawal rate as this can be an important source of
bias. Data were available for 87 of the 101 subjects, and
mean compliance with treatment was 92%. Subjects
who failed to complete did so largely for personal rea›
sons, with no difference between salmeterol and
placebo in the number or reasons for withdrawal.
The addition of salmeterol for six months was asso›
ciated with a reduction in inhaled steroid use and
symptoms and an increase in forced expiratory volume
in one second and morning and evening peak expira›
tory flow. We have presented the findings over the last
five months of treatment to reduce any crossover
effects and to allow time for subjects to adjust their
inhaled steroid dose in response to change in
treatment. We found no carry over effects apart from
minimum heart rate, which was omitted from further
analysis, and no treatment baseline interactions except
for a weak relation with baseline log inhaled steroid
dose, which we explored further.
The mean inhaled steroid dose was 17% lower with
salmeterol than with placebo during the last five
months of treatment. The subjects on lower doses of
inhaled steroid initially had a slightly higher percent›
age fall in inhaled steroid dose with salmeterol, though
there was considerable overlap with those initially on a
higher dose. The 17% reduction should not be
interpreted as the steroid sparing dose of salmeterol as
subjects had limited freedom to reduce their inhaled
steroid dose (by two puffs a day maximum from the
dose at randomisation so that the minimum dose pos›
sible was 100 ìg twice daily). If all subjects had reduced
their dose to the minimum allowed the geometric
mean dose would have been 387 ìg (rather than 561
ìg). The decision to limit the reduction in dose was
based on current consensus guidelines14 15 and an
appreciation that peak expiratory flow is only one
measure of asthma control. Salmeterol was associated
with fewer symptoms and no difference in exacerba›
tions or use of rescue oral steroids compared with pla›
cebo, despite the reduction in inhaled steroid dose.
Relatively few subjects had an exacerbation during
the study, probably because the management plan
ensured early detection of deterioration and encour›
aged prompt treatment. Most studies comparing
salmeterol with placebo or a short acting â2 agonist
have found no difference in exacerbations, although
most had insufficient power to detect this.4 5 8›11 A large
surveillance study found a smaller reduction in
withdrawals owing to asthma with salmeterol com›
pared with salbutamol, although the trend for deaths
was in the opposite direction.20 Airway inflammation is
not reduced by salmeterol or the shorter acting â2 ago›
nists compared with inhaled steroids12 13; whether this
is relevant to the frequency or severity of exacerbations
is uncertain.
This is the first controlled study to compare
salmeterol 50 ìg twice daily with placebo for more
than three months. The effect of salmeterol was main›
tained over six months, with no evidence of tolerance
for any clinical end point. When we looked at
bronchodilator responsiveness to salbutamol baseline
forced expiratory volume in one second was higher
with salmeterol, but the final forced expiratory volume
in one second achieved was identical in the two
treatment periods, as in previous studies.21 22 We
interpret this as showing that bronchodilator respon›
siveness is maintained after regular salmeterol
treatment.
The PD20 methacholine was higher after salmeterol
than placebo, although the differences were small. The
magnitude of the effect will be affected by the timing of
the measurement, 8›14 hours after treatment, when
some residual effect of salmeterol would be expected,
and possibly by the development of tolerance, as seen
with other â2 agonists
23 24 as well as salmeterol.25 26
Salmeterol, like other â2 agonists, causes systemic
effects such as hypokalaemia and tremor when given in
high doses.27 28 Such effects are rare with a 50 ìg twice
daily dose,8 28 and there was no difference in adverse
effects, serum potassium concentrations, or 24 hour
heart rate between treatments.
The design of this study is relevant to how
salmeterol is likely to be used in clinical practice, and
the findings provide some reassurance that if
salmeterol is introduced at an earlier point in
treatment14 (at step 3 rather than step 4 of the
guidelines for treatment of asthma) a subsequent
reduction in inhaled steroid dose is unlikely to have a
detrimental effect in patients who followed an
appropriate management plan.
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Molecular investigation into outbreak of HIV in a Scottish
prison
D L Yirrell, P Robertson, D J Goldberg, J McMenamin, S Cameron, A J Leigh Brown
Abstract
Objectives: To support already established
epidemiological links between inmates of Glenochil
prison positive for HIV infection by using molecular
techniques and thus provide evidence of the extent of
acquisition during a recent outbreak of the disease
resulting from needle sharing. To identify possible
sources of the outbreak, and to demonstrate the
ability of the methodology to make further links
beyond the original outbreak.
Design: Viral sequences obtained from the blood of
HIV positive prisoners previously identified by
standard epidemiological methods were compared
with each other and with sequences from other
Scottish patients.
Setting: Glenochil prison for men, central Scotland.
Subjects: Adult inmates and their possible contacts.
Results: Phylogenetic analysis of viral sequences in
two different genomic regions showed that 13 of the
14 HIV positive prisoners had been infected from a
common source. Previous research had shown that six
of these had acquired their infection in Glenochil;
molecular evidence suggests that more than double
this number were infected while incarcerated. Virus
from two long term HIV positive patients who were in
the prison at the time of the outbreak but who were
not identified in the original or subsequent surveys
was sufficiently different to make it unlikely that they
were the source. A viral sequence from heterosexual
transmission from one inmate showed the ability of
these techniques to follow the infection through
different routes of infection.
Conclusion: The number of prisoners infected with
HIV during the 1993 outbreak within Glenochil
prison was more than twice that previously shown.
This shows the potential for the spread of bloodborne
diseases within prisons by injecting drugs.
Introduction
Inmates who inject drugs in prison are at risk of
acquiring HIV and other bloodborne infections.1
Although several investigations into the prevalence of
HIV infection have been conducted in correctional
institutions,2›4 measuring the incidence of HIV
transmission within prison is difficult because of prob›
lems in identifying the probable date of transmission.
The first report to provide direct evidence of an
outbreak of HIV occurring within a prison docu›
mented an HIV counselling and testing initiative of
inmates from HM Prison Glenochil conducted at the
end of June 1993; this exercise was precipitated by the
reporting of eight symptomatic cases of acute hepatitis
B and two diagnosed cases of primary infection with
HIV between April and June 1993.5 Widespread drug
injecting and needle sharing were also reported by the
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prison doctor, and the possibility of an outbreak was
recognised.
Of 378 inmates who were incarcerated during the
survey period, 227 (60%) agreed to counselling and
subsequently to an HIV test. This resulted in the iden›
tification of a further 12 cases of HIV infection. From
known dates of imprisonment in Glenochil, the most
recent negative result for HIV antibody, the presence
of p24 antigenaemia, and clinical presentation of
symptomatic primary HIV infection, it was concluded
that eight inmates had acquired HIV infection while in
prison. Of these eight, two could possibly have
acquired HIV in another prison before transfer, thus
for only six patients was there definite evidence of an
infection acquired in Glenochil itself.5
HIV evolves at a rate estimated to be one million
times faster than that of higher eukaryotes.6 This is
because the rate of viral replication is rapid (about 1010
viral particles are generated daily)7 8 and the virus’s
reverse transcriptase enzyme, which is essential for
replication, is error prone and lacks any proofreading
capacity. Thus, any one infected person harbours a
complex population of closely related but
distinguishable viruses. Whereas this is a major
problem for the design of therapeutic interventions, it
can facilitate certain epidemiological investigations. An
epidemiological link among infected people is likely if
their viral nucleic acid sequences are similar and
unlikely if they are different. To compare sequences
from different people it is important to study the most
appropriate region of the viral genome. The env gene
evolves at such a rapid rate that an epidemiological link
can be detected only if the interval between
transmission and sampling is extremely short. In
contrast, the pol gene is highly conserved in people not
taking antiviral drugs and can be very similar among
those who acquired their HIV infection from unrelated
sources. The p17 region of the gag gene has been
shown to be effective as a molecular epidemiological
tool particularly when used in conjunction with the env
gene.9
Molecular epidemiological analysis of nucleotide
sequence data has been used in several investigations
of HIV›1 transmission.10›14 Analysis of nucleotide
sequence data established the occurrence and extent of
an infection cluster associated with a dental practice in
Florida10›15 and distinguished between two possible
sources of infection in an investigation by the
Maryland Department of Health.13 Similar methods
were used here to conduct a molecular epidemiologi›
cal investigation on samples from the HIV infected
inmates identified at the time of the counselling and
testing exercise.5 The aim of the study was to determine
if all diagnosed cases were, as postulated, linked and if
there had been a single or multiple source of infection.
Subjects and methods
Samples
Between June and August 1993 peripheral blood
mononuclear cells were obtained from 13 of the 14
HIV positive inmates identified in the previously pub›
lished survey (cases 1›7 and 9›14).5 In addition, a
plasma sample was obtained from the other member
of the cohort (case 8), from whom a follow up whole
blood sample was unavailable. Despite repeated
attempts only a single viral sequence from this sample
was generated. Case numbers used in this paper
correspond with those published elsewhere.5
Peripheral blood mononuclear cells and plasma
samples were obtained from two long term patients
infected with HIV (S1 and S2, respectively) who had
been identified by their general practitioners, who, in
response to publicity surrounding the outbreak,
realised that they had been in Glenochil during the “at
risk” period (January to June 1993). They were
therefore not considered part of the outbreak but as
putative sources. Peripheral blood mononuclear cells
were also obtained from the wife of one inmate (HC1),
who seroconverted after heterosexual contact with her
husband after his release from prison.
Sequencing
Proviral DNA and viral RNA was extracted from
patients’ peripheral blood mononuclear cells and
plasma, respectively, and amplified by using nested
polymerase chain reaction in both the V3/V4 region
of the env gene and the p17 region of the gag gene.16›19
Direct sequencing of polymerase chain reaction prod›
ucts derived from single molecules was carried out by
using an Applied Biosystems 373A automated
sequencer.20 Ideally, two sequences from each region
from each person were generated but because of the
quality of starting material this was not always possible.
Phylogenetic analyses
In the case of gag sequences a maximum likelihood
phylogenetic tree, rooted by the inclusion of the
subtype D isolate HIV›1ELI, was obtained for duplicate
sequences from cases 1, 2, 4›7, and 9›14 and single
sequences from cases 3 and 8 and compared with
duplicate sequences from the heterosexual contact of
case 5 (HC1) and one putative source S1 (see fig 1).
Single sequences within the homologous region of
HIV, from seven injecting drug users, five haemophilic
subjects, three heterosexual contacts of injecting drug
users, all of whom were Scottish and not known to be
related for HIV transmission, and 10 unrelated subtype
B isolates obtained from international databases were
included for comparison.
A similar tree was used to compare a 246 base pair
region of the env gene (see fig 2). Duplicate sequences
from Glenochil cases 1, 2, 4›7, and 9›13, a single
sequence from case 3, and duplicate sequences from
the sexual contact (HC1) and both putative sources S1
and S2 were aligned with the homologous region from
14 haemophilic subjects and five injecting drug users
and heterosexual contacts, all of whom were Scottish
and not known to be related for HIV transmission, and
10 unrelated subtype B isolates from international
databases.
Results
Analysis of p17 gag sequences
This analysis grouped 13 of the 14 Glenochil inmates
into a single cluster; indeed 16 sequences from nine
different people had identical sequences over the 350
base pairs used for the comparison (fig 1). The hetero›
sexual contact of case 5 (HC1) clearly groups within
the main cohort whereas the sequence from putative
Papers
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source S2 groups with other Scottish drug users unre›
lated to the outbreak. The single sequence obtained
from the 14th Glenochil inmate (case 8) was distinct.
Analysis in a wider background showed that it grouped
among sequences found in several homosexual men
from Scottish cities (A J Leigh Brown et al, unpublished
data).
Env gene sequences
Figure 2 shows the maximum likelihood phylogenetic
tree that illustrates that all of the 12 Glenochil patients
from whom sequences were obtained in this particular
region not only fall into a single cluster, supporting the
gag data, but also have no specific association with
either of the potential sources of the infection.
Statistical assessment of phylogenetic analysis
The phylogenetic trees for both gag and env were
tested by bootstrap resampling and results presented
as a percentage. The bootstrap procedure identifies
clusters of sequences which are still present after the
nucleotide dataset has been resampled. Clusters that
are present in 70% or more bootstrap samples are
considered to be well supported.15 Every significant
group—that is, supported in 70% or more samples—is
identified in the figures. With the single exception of
case 8 the entire Glenochil cohort has a bootstrap sup›
port of 100% in the p17 gag tree and of 85% in the V3
env region tree. The only other supported clusters
(apart from multiple sequences from the same patient)
were those which have previously been described for
haemophilic subjects in Edinburgh.19
A more specific evaluation was required to test the
possibility of linkage between the major Glenochil
cluster of sequences and either of the putative sources.
This was done by constructing alternative trees in
which either of these two patients was grouped with
the cohort and testing the significance of the difference
by a maximum likelihood ratio test.21 Three rearrange›
ments of the V3 tree data were tested by artificially
altering the tree to see if the result was a significantly
worse fit. Versions that either grouped any individual
members of the main Glenochil cluster with other
Scottish drug users or that introduced putative source
S2 into the main Glenochil cluster were significantly
less likely (P < 0.05) than that shown in figure 2. The
rearrangement that grouped the other putative source
(S1) with this group, however, was not significantly less
likely than the tree shown.
Similar analyses on the gag data were performed.
Both the inclusion of sequences from either case 8 or
putative source S2 into the main Glenochil cluster
resulted in a tree that was significantly less likely than
the one shown (P < 0.05).
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Summary of results
The similarity between the viral sequences from differ›
ent people is remarkable. In the gag region the average
divergence within the cluster of 13 was 0.2%. This
compares with an average divergence between Scottish
drug users of 5.4% (P < 0.001) and subtype B viruses
generally of 6.7%. Even within the V3 region of the
envelope gene where the average divergence within B
subtypes and Scottish drug users is higher at 11.4%
and 8.6%, respectively, divergence within the cohort is
only 0.65%. Indeed, the values for the cohort are com›
parable with or even lower than those that would be
expected from sequential samples obtained from the
same person. As six of this group had previously been
shown to have acquired their infection while in Gleno›
chil prison,5 it follows that all 13 were part of the same
epidemiological cluster. The sequence from the 14th
patient (case 8) is significantly different. The two puta›
tive sources of infection (S1 and S2), identified
serendipitously by local general practitioners and not
by prison surveys, were known to have acquired their
infection before the outbreak in Glenochil and are
therefore not considered as part of this particular
cohort. The sequences from these two people were suf›
ficiently different from the cluster of 13 for us to
discount linkage, although only in the case of S2 was
this significant. The linkage of sequences from the het›
erosexual contact HC1 showed a significant linkage
with the cluster of 13.
Discussion
HIV in prisons
The prevalence of HIV infections in different prisons
within and across countries can vary considerably.
Prevalence has ranged from none in a young male
offenders institution in Scotland3 to 33.6% in an adult
prison in Catalonia22 and to over 50% in a female cor›
rectional facility in New York City.2 Most HIV infected
inmates probably acquired their infection through
injecting drug use, very little being ascribed to
homosexual contact.23 In Australia an estimated half of
male injecting drug users have at some time been
imprisoned,4 and several reports have indicated that
not only do a high proportion of drug users continue
to inject and share injecting equipment while incar›
cerated but some inject for the first time while in
prison.1 24 25 It is unknown but could be expected that
outbreaks such as that reported in Glenochil prison
are more widespread. Several surveys in Scottish
prisons have indicated that the medical authorities
have underestimated the number of HIV positive
people in their prison by about 25%.1 26 For example,
the initial survey of Glenochil prison in June 19935
identified 14 HIV positive prisoners, whereas a follow
up study 12 months later estimated that up to 20
inmates had been part of the outbreak.27
Application of molecular technology
Before this investigation the combination of conven›
tional serological data and dates of prison entry had
been used to show that eight out of the 14 HIV positive
inmates of Glenochil prison had acquired their
infection while incarcerated, although two of these
could have been infected in another prison before
transfer. By applying molecular techniques we have
shown that 13 of the 14 HIV positive subjects were
infected with an almost identical virus. This finding
strongly suggests that not only were these men infected
while in Glenochil prison but also the infection came
from a single source. As the two inmates previously
known to be infected (S1 and S2) had viral sequences
that were unrelated to those seen in the cohort, we
conclude that the source of the infection was either an
unidentified Glenochil inmate or one of the 13 cases
who acquired his infection outside the prison just
before being incarcerated there early in 1993. Infection
was then probably transmitted by this single source
directly or indirectly along a chain to either 12 or 13
inmates over a short period of time. The rapid spread
of HIV among the cohort probably occurred while
concentrations of circulating virus were at their highest
in each subject during the interval between infection
and seroconversion.28
The 14th person identified by the survey (case 8)
was clearly infected with a different virus, with an aver›
age sequence divergence from the rest of the cohort of
12.4%. Only a single sample, which had shown an early
banding pattern on western blot characteristic of sero›
conversion, was available for this patient. In the
absence of a follow up sample it seems that he was
infected at the same time as the others but not from the
same source. Indeed, although no sex between men
was reported from the Glenochil survey, analysis
within a more extensive dataset shows that the
sequence from case 8 is most closely related to viral
sequences obtained from homosexual men, suggesting
a different source of infection. In this context the
Glenochil cohort will refer to the 13 patients infected
with a similar viral strain.
Public health implications
The application of molecular techniques to trace the
origin or chain of an outbreak of infection is not new
and has been particularly useful in the context of food
poisoning. For HIV the benefits of viral sequencing
may also be considerable. Before 1993 no outbreak of
HIV within a prison had been reported. While there
was much indirect evidence to suggest that epidemics
had occurred in prisons, the absence of proof made it
difficult for those working in the specialties of HIV and
AIDS to convince prison officials and authorities that
preventive measures needed to be implemented.
The finding that at least 13 prisoners definitely
acquired their infection inside Glenochil prison was
the catalyst for the introduction of a wide range of
harm reduction measures for people who inject in
prisons throughout Scotland. These include the provi›
sion of bleach tablets for sterilising injecting equip›
ment; a methadone detoxification programme for
inmates; the availability of hepatitis B vaccine;
increased training for prison officers; and improved
access to drug harm minimisation counselling for pris›
oners. Thus the public health implications of this
molecular investigation have already been consider›
able. As drug injecting inside prison is a global
problem, it is hoped that the findings of this study will
have far reaching consequences.
The Glenochil cohort strain belongs to the subtype
B category, which is the predominant strain in Europe
and North America. Non›B subtypes, which are preva›
lent in the developing world, however, are being
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detected increasingly in the United Kingdom as a con›
sequence of travel and mixing of populations. Of par›
ticular concern is HIV subtype E, which is highly
prevalent among heterosexuals in South East Asia and
for which there is laboratory evidence of properties
that suggest that it may be transmitted heterosexually
more efficiently than B subtype strains (A J Leigh
Brown et al, unpublished data). Already the public
health laboratory service in England has identified sev›
eral different viral subtypes.29 It is thus essential that
surveillance of HIV infection includes not only data on
numbers of prevalent cases but also information on
strain subtype. Such monitoring would identify the
entry of new strains into the population from abroad,
the occurrence of which could have a major impact on
the dynamics of HIV spread locally.
Future studies
Further work that has stemmed from the findings of
this study is under way. The Glenochil cohort is unique;
all members are of similar age, the same sex, ethnic
group, and risk category, and all were infected with the
same virus at the same time. This feature affords the
opportunity to study progression of HIV disease in a
cohort for which viral as well as host factors are
controlled. Although the cohort comprises 13 cases,
there could be more. In July 1994 a voluntary
anonymous prevalence study of HIV infection among
inmates of Glenochil prison estimated that 20 had
been infected during January to June 1993. It is there›
fore likely that some cases have yet to be diagnosed or
associated with the Glenochil outbreak. Accordingly,
approval has been obtained to link the prison register
for the period January to June 1993 with the HIV reg›
ister held at the Scottish Centre for Infection and Envi›
ronmental Health; the latter contains details on all new
laboratory diagnoses in Scotland. If a match is
identified efforts will be made, on condition of consent,
to verify the association through an interview with the
subject and molecular investigations being conducted
on his blood to compare his strain with that of the
original cohort.
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Key messages
+ Originally, standard serological studies
established that six out of 14 HIV positive
people had acquired their infection in
Glenochil prison in 1993
+ A subsequent survey estimated that up to 20
prisoners were HIV positive at that time
+ Molecular linkage techniques showed that 13 of
the original 14 infected men had viral
sequences similar enough to indicate that one
source of infection was common to all
+ Molecular techniques provide a powerful
epidemiological tool either to link or to
distance infections with HIV
+ Injecting drug use is a potentially explosive
health care problem in prisons
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Residential and occupational exposure to sunlight and
mortality from non›Hodgkin’s lymphoma: composite
(threefold) case›control study
D Michal Freedman, Shelia Hoar Zahm, Mustafa Dosemeci
Abstract
Objective: To determine whether non›Hodgkin’s
lymphoma mortality is associated with sunlight
exposure.
Design: Three case›control studies based on death
certificates of non›Hodgkin’s lymphoma, melanoma,
and skin cancer mortality examining associations with
potential sunlight exposure from residence and
occupation.
Setting: 24 states in the United States.
Subjects: All cases were deaths from non›Hodgkin’s
lymphoma, melanoma, and non›melanotic skin
cancer between 1984 and 1991. Two age, sex, and race
frequency matched controls per case were selected
from non›cancer deaths.
Main outcome measures: Odds ratios for
non›Hodgkin’s lymphoma, melanoma, and skin
cancer from residential and occupational sunlight
exposure adjusted for age, sex, race, socioeconomic
status, and farming occupation.
Results: Non›Hodgkin’s lymphoma mortality was not
positively associated with sunlight exposure based on
residence. Both melanoma and skin cancer were
positively associated with residential sunlight
exposure. Adjusted odds ratios for residing in states
with the highest sunlight exposure were 0.83 (95%
confidence interval 0.81 to 0.86) for non›Hodgkin’s
lymphoma, 1.12 (1.06 to 1.19) for melanoma, and
1.30 (1.18 to 1.43) for skin cancer. In addition,
non›Hodgkin’s lymphoma mortality was not positively
associated with occupational sunlight exposure (odds
ratio 0.88; 0.81 to 0.96). Skin cancer was slightly
positively associated with occupational sunlight
exposure (1.14; 0.96 to 1.36).
Conclusions: Unlike skin cancer and to some extent
melanoma, non›Hodgkin’s lymphoma mortality was
not positively associated with exposure to sunlight.
The findings do not therefore support the hypothesis
that sunlight exposure contributes to the rising rates
of non›Hodgkin’s lymphoma.
Introduction
Incidence and death rates for non›Hodgkin’s lymphoma
have risen rapidly in recent decades throughout the
world.1 Neither changes in diagnostic practices nor
known and suspected risk factors seem to account fully
for the increases.2 Several investigators have hypoth›
esised that increased exposure to sunlight may have
contributed to the rising rates of non›Hodgkin’s
lymphoma.3›8 They note that melanoma and other skin
cancer rates have also risen rapidly worldwide,4 that
non›Hodgkin’s lymphoma and skin cancer are associ›
ated in individual patients,4 6 and that ultraviolet stimula›
tion is experimentally immunosuppressive.3 7 Ecological
studies that have explored this hypothesis have had con›
flicting results.3 7›9 None, however, examined sources of
sunlight exposure other than residence.
We conducted a population based case›control study
of non›Hodgkin’s lymphoma mortality in the United
States. As an improvement over ecological studies, we
assessed potential sunlight exposure from both the
occupational and the residential records on the death
certificate. The findings for non›Hodgkin’s lymphoma
were compared with findings for melanoma and
non›melanotic skin cancer, two diseases regarded as
causally linked to sunlight exposure.10
Methods
Since 1984 the American National Cancer Institute
and the National Institute for Occupational Safety and
Health have supported the creation of a 24 state
mortality database, which includes coding of occupa›
tion and other information from death certificates, as
described by Figgs et al.11 Cases included all deaths
between 1984 and 1991 from non›Hodgkin’s
lymphoma (International Classification of Diseases,
ninth revision (ICD›9), codes 200 and 202 (excluding
202.2›202.6)), melanoma (code 172), and non›
melanotic skin cancer (codes 173, 154.3, and 187.7) in
people aged 20 or over identified as white or African
American. Two controls per case were selected from
non›cancer deaths in the database and matched for
frequency by sex, race, and five year age group.
Potential sunlight exposure was assessed by
residence and usual occupation recorded on the death
certificate. The annual mean daily solar radiation
(which includes ultraviolet and visible light) for the
state of residence at death and state at birth were
obtained from United States Weather Bureau data.12
Each state was characterised at one of three levels
based on the predominant solar radiation contour
crossing the state. The 24 states reflected all regions of
the country (see table 1).
Occupations were classified by an industrial
hygienist (MD) into four categories: indoor work, work
that combined indoor and outdoor exposure, outdoor
work by non›farmers, and farming. Farmers were
categorised separately because some studies have sug›
gested that farmers may be at increased risk of
non›Hodgkin’s lymphoma due to exposure to pesti›
cides, a potential confounder for which we could not
otherwise control.13 Occupation was also used to create
an index of socioeconomic status, with five levels based
on a method of scoring devised by Green.14
Homemakers, retirees, and students were not assigned
a socioeconomic level but were controlled for
separately. Cases and controls with no identified occu›
pation on the death certificate (about 4%) were
excluded from analysis.
The multivariate model included age, sex, race,
residential sunlight exposure, occupational sunlight
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exposure, and socioeconomic status for the entire
population, and was analysed by race and sex groups
and by age ( < 45 years, >45 years). Birthplace, which
was highly correlated with residence at death, was
excluded from the model. The effects of skin
pigmentation were assessed by classifying subjects
based on national origin and race as recorded on the
death certificate.
The measure of association was the mortality odds
ratio and 95% confidence interval derived by standard
logistic regression methods in SAS.15
Results
Table 1 gives the numbers of cases and controls for
non›Hodgkin’s lymphoma, melanoma, and non›
melanotic skin cancer deaths by age, sex, race, skin
pigmentation, residence, birthplace, occupational
category, and socioeconomic status. Roughly a quarter
to one third of subjects lived in states with the highest
levels of sunlight. Around 3›5% had outdoor
non›farming jobs.
Table 2 gives the odds ratios for non›Hodgkin’s
lymphoma, melanoma, and non›melanotic skin cancer
mortality adjusted for age, sex, race, residence, occupa›
tional sunlight exposure, and socioeconomic status.
For non›Hodgkin’s lymphoma the adjusted odds ratios
declined significantly with increasing exposure to sun›
light based on residence and occupational category. In
contrast, the adjusted odds ratios for melanoma and
skin cancer and residential exposure increased, the risk
of skin cancer rising significantly to 1.30 among
subjects who resided in states with the highest sunlight
exposure.
Table 1 Characteristics of non›Hodgkin’s lymphoma, melanoma, and non›melanotic skin cancer cases and controls.† Data expressed
as numbers (percentages) of subjects
Non›Hodgkin’s lymphoma Melanoma Skin cancer
Cases
(n=33 407; 34%)
Controls
(n=65 843; 66%)
Cases
(n=12 156; 34%)
Controls
(n=23 845; 66%)
Cases
(n=4619; 33%)
Controls
(n=9170; 67%)
Age (years):
20›44 2 320 (7) 4 413 (7) 2 290 (19) 4 361 (18) 270 (6) 526 (6)
45›54 2 587 (8) 4 994 (8) 1 753 (14) 3 378 (14) 401 (9) 798 (9)
55›64 5 646 (17) 11 089 (17) 2 405 (20) 4 742 (20) 912 (20) 1803 (20)
65›74 9 885 (30) 19 590 (30) 2 753 (23) 5 474 (23) 1163 (25) 2302 (25)
>75 12 969 (39) 25 757 (39) 2 955 (24) 5 890 (25) 1873 (41) 3741 (41)
Sex:
Female 16 609 (50) 32 822 (50) 4 900 (40) 9 590 (40) 1566 (34) 3125 (34)
Male 16 798 (50) 33 021 (50) 7 256 (60) 14 255 (60) 3053 (66) 6045 (66)
Race:
Black 1 818 (5) 3 535 (5) 208 (2) 400 (2) 410 (9) 810 (9)
White 31 589 (95) 62 308 (95) 11 948 (98) 23 445 (98) 4209 (91) 8360 (91)
Pigmentation:
Fair‡ 1 806 (5) 3 782 (6) 691 (6) 1 346 (6) 232 (5) 500 (5)
Other white 29 783 (89) 58 526 (89) 11 252 (93) 22 099 (93) 3977 (86) 7860 (86)
Black 1 818 (5) 3 535 (5) 208 (2) 400 (2) 410 (9) 810 (9)
Residence§:
Low sun 11 553 (35) 21 244 (32) 3 646 (30) 7 613 (32) 1330 (29) 2972 (32)
Moderate sun 13 529 (41) 26 334 (40) 4 792 (39) 9 384 (39) 1839 (40) 3692 (40)
High sun 8 325 (25) 18 265 (28) 3 718 (31) 6 848 (29) 1450 (31) 2506 (27)
Birthplace{:
Low sun 11 000 (33) 20 496 (31) 3 797 (31) 7 626 (32) 1252 (27) 2757 (30)
Moderate sun 14 290 (14) 27 861 (42) 5 135 (42) 10 023 (42) 2007 (43) 3885 (42)
High sun 6 863 (21) 15 245 (23) 2 870 (24) 5 478 (23) 1218 (26) 2147 (23)
Occupation:
Indoor 17 054 (51) 31 125 (47) 6 574 (54) 11 734 (49) 2225 (48) 4393 (48)
Mixed 14 081 (42) 29 502 (45) 4 723 (39) 10 166 (43) 1849 (40) 3793 (41)
Outdoor (non›farmer) 867 (3) 2 302 (4) 406 (3) 993 (4) 250 (5) 441 (5)
Farmer 1 405 (4) 2 914 (4) 453 (4) 952 (4) 295 (6) 543 (6)
Socioeconomic status¶:
1 Low 3 653 (11) 8 917 (14) 1 263 (10) 3 151 (13) 799 (17) 1530 (17)
2 4 889 (15) 11 055 (17) 1 774 (15) 4 497 (19) 821 (18) 1715 (19)
3 9 771 (29) 17 815 (27) 3 910 (32) 7 015 (29) 1320 (29) 2612 (28)
4 5 177 (15) 8 001 (12) 2 153 (18) 3 245 (14) 575 (12) 1148 (13)
5 High 1 449 (4) 1 954 (3) 754 (6) 878 (4) 187 (4) 311 (3)
†Ratio of controls to cases was slightly less than 2.0 owing to exclusion of subjects with no occupational information.
‡Subjects were characterised as fair skinned if they were white and their national origins were identified as British, Irish, German, Scandinavian, Polish, or other
northern European.
§Levels of sun exposure were categorised based on annual mean daily solar radiation reported by Garland et al12 for state reported as residence at time of death.
This was sometimes outside the 24 states in which deaths occurred. “Low” included the following states and other areas: Alaska, Connecticut, Maine,
Massachusetts, Michigan, Minnesota, New Hampshire, New York, Ohio, Oregon, Pennsylvania, Rhode Island, Vermont, Washington, Wisconsin, Canada. “Moderate”
included Arkansas, Delaware, District of Columbia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maryland, Missouri, Montana, Nebraska, New Jersey, North
Carolina, North Dakota, South Carolina, Tennessee, Virginia, and West Virginia. “High” included Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii,
Louisiana, Mississippi, Nevada, New Mexico, Oklahoma, South Carolina, Texas, Utah, Wyoming, Puerto Rico, Virgin Islands, Guam, Cuba, and Mexico. (States in bold
are the 24 states from the mortality database.)
{Levels of sun exposure were categorised as above for state identified as state of birth. Cumulative percentage is less than 100 because birthplace could not be
identified in a few cases and controls.
¶Cumulative percentage is less than 100 because socioeconomic status could not be identified for retirees, homemakers, and students.
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The risk of non›farming occupational sunlight
exposure for skin cancer was slightly but not
significantly raised in outdoor workers (odds ratio 1.14;
table 2). In melanoma, however, there was no apparent
pattern for non›farming occupational sunlight expo›
sure. Farmers were at significantly increased risk
compared with indoor workers for non›Hodgkin’s
lymphoma and melanoma but not skin cancer.
Socioeconomic status increased the association with
non›Hodgkin’s lymphoma and melanoma but gener›
ally not with skin cancer. Similar results were obtained
in the crude analysis, with the exception of the odds
ratio for farming; this was significantly decreased for
non›Hodgkin’s lymphoma and melanoma.
The negative residential associations identified for
non›Hodgkin’s lymphoma in the total population were
also seen in the multivariate model in the sex, race, and
age subpopulations. The deficit of non›Hodgkin’s
lymphoma risk associated with residential sunlight
exposure was most pronounced in subjects aged 44
years or less (highest versus lowest sunlight region:
odds ratio 0.69; 95% confidence interval 0.61 to 0.79).
The odds ratio for occupational exposure among men
reflected that of the total population. Among women
the odds ratios were raised, though not significantly so.
The risk of melanoma and skin cancer increased
with residential exposure among white people and
subjects aged over 44. No pattern was evident for
African Americans. There was also no clear pattern for
melanoma or skin cancer risk associated with occupa›
tional exposure across the sex, race, or age groups,
except that risk of skin cancer increased among
subjects aged over 44.
Increased potential sunlight exposure was associ›
ated with declining non›Hodgkin’s lymphoma risk in
each residential area and for each occupational
category, the greatest decline occurring among
outdoor workers in areas receiving the most sun›
light (table 3). The effect was strongest in younger
people, among whom the odds ratio declined to 0.44
(0.28 to 0.67) in subjects in occupations and states with
the highest sunlight exposure. The risks for skin cancer
generally increased with potential residential or
occupational sunlight exposure. With melanoma, how›
ever, the risk from residential exposure did not
increase among outdoor workers; nor did the risk
increase with occupational sun exposure, except
among subjects with low residential exposure.
Odds ratios for non›Hodgkin’s lymphoma
increased with skin pigmentation from 1.0 among
subjects with northern European ancestry to 1.10
(1.04 to 1.17) among other white groups and 1.26 (1.16
to 1.37) among African Americans. There was no
significant association with melanoma or skin cancer.
Among subjects with fair pigmentation the odds ratio
for non›Hodgkin’s lymphoma in the highest sunlight
region was 0.92 (0.80 to 1.06). In this group the risks
associated with this exposure were raised for
melanoma (odds ratio 1.44; 1.15 to 1.79) and skin can›
cer (1.56; 1.06 to 2.29).
Discussion
This study found no evidence of an excess risk of non›
Hodgkin’s lymphoma mortality associated with poten›
tial sunlight exposure. The results generally showed
decreased risk among people with the heaviest
exposure. Though the methods used were crude, they
produced associations between sunlight exposure and
the risk of melanoma and skin cancer mortality. Most
other research on non›Hodgkin’s lymphoma and sun›
light has been limited to ecological data with exposure
potential determined by residence alone. This analyti›
cal study improved exposure ascertainment by using
individual data on occupation, state of birth,
socioeconomic status, skin pigmentation, and resi›
dence.
Associations with exposure to sunlight
The incidence of skin cancer is thought to be directly
associated with cumulative sun exposure.10 16 Generally,
studies of skin cancer incidence and total sun exposure
have found associations with odds ratios between 1.2
and 11.0.17 Consistent with this, we found positive asso›
ciations between skin cancer mortality and residential
and occupational surrogates for exposure to sunlight
exposure. In contrast, melanoma was not as closely
associated with our indicators of sunlight exposure.
The relation of melanoma to sunlight, however, is
more complex, with age of exposure3 10 and intermit›
Table 2 Odds ratios (95% confidence intervals) for non›Hodgkin’s lymphoma,
melanoma, and non›melanotic skin cancer mortality associated with indicators of
sunlight exposure and socioeconomic status, adjusted for age, sex, race, and other
factors†
Non›Hodgkin’s
lymphoma Melanoma Skin cancer
Residence‡:
Low sun 1.0 1.0 1.0
Moderate sun 0.95 (0.92 to 0.98) 1.08 (1.02 to 1.13) 1.12 (1.02 to 1.22)
High sun 0.83 (0.81 to 0.86) 1.12 (1.06 to 1.19) 1.30 (1.18 to 1.43)
Occupation:
Indoor 1.0 1.0 1.0
Mixed 0.95 (0.91 to 0.99) 0.92 (0.87 to 0.98) 0.95 (0.85 to 1.05)
Outdoor (non›farmer) 0.88 (0.81 to 0.96) 0.99 (0.87 to 1.12) 1.14 (0.96 to 1.36)
Farmer 1.31 (1.21 to 1.42) 1.31 (1.14 to 1.52) 1.08 (0.89 to 1.31)
Socioeconomic status:
1 Low 1.0 1.0 1.0
2 1.21 (1.13 to 1.28) 1.11 (1.00 to 1.23) 0.97 (0.84 to 1.12)
3 1.49 (1.40 to 1.57) 1.55 (1.41 to 1.71) 1.03 (0.90 to 1.18)
4 1.73 (1.62 to 1.84) 1.81 (1.63 to 2.00) 1.01 (0.86 to 1.18)
5 High 2.02 (1.86 to 2.20) 2.39 (2.10 to 2.72) 1.22 (0.98 to 1.52)
† Odds ratios were calculated from logistic regression, adjusted for age (categorised as in table 1), sex,
race, residence, occupational sun exposure, and socioeconomic status.
‡ See table 1.
Table 3 Odds ratios (95% confidence intervals) for non›Hodgkin’s lymphoma,
melanoma, and non›melanotic skin cancer mortality by occupational sunlight exposure
and residential sunlight exposure, adjusted for age, sex, race, socioeconomic status,
and farming status†
Occupational exposure
Residence‡
Low sun Moderate sun High sun
Non›Hodgkin’s lymphoma
Indoor 1.0 1.0 (0.96 to 1.04) 0.86 (0.82 to 0.90)
Outdoor (non›farmer) 0.89 (0.77 to 1.03) 0.87 (0.76 to 0.99) 0.74 (0.64 to 0.86)
Melanoma
Indoor 1.0 1.10 (1.03 to 1.19) 1.18 (1.09 to 1.27)
Outdoor (non›farmer) 1.22 (0.99 to 1.50) 1.05 (0.86 to 1.29) 0.96 (0.76 to 1.20)
Skin cancer
Indoor 1.0 1.06 (0.94 to 1.19) 1.28 (1.12 to 1.46)
Outdoor (non›farmer) 0.98 (0.71 to 1.34) 1.42 (1.08 to 1.84) 1.36 (1.01 to 1.83)
† Odds ratios were calculated from logistic regression; adjustments for age were based on age categories in
table 1.
‡ See table 1.
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tent intense exposure10 18 20 thought to have a role.
Studies of melanoma incidence and residential or
overall sun exposure have reported significant associa›
tions with odds ratios or relative risk ratios of about
1.7.16 18 In this study residential sunlight exposure at the
times of death and birth was associated with
melanoma.
Occupational sunlight exposure, however, was not
associated with melanoma. The absence of an overall
occupational association seems to reflect varied
occupational associations among residential regions.
In both the moderate and high sunlight regions
outdoor work was associated with lower risk than
indoor work, which might be expected if melanoma is
more a function of intermittent exposure than
continuous exposure. Occupational studies of
melanoma risk and outdoor exposure present
divergent findings, studies indicating no association
with outdoor work19 or that outdoor work may protect
against melanoma.18 20
In marked contrast with the associations with
melanoma and skin cancer, we found that both
residential and occupational sunlight exposure were
inversely associated with non›Hodgkin’s lymphoma
and that these negative associations characterised most
of the sex, race, and age subpopulations. Moreover, risk
declined consistently across residential exposure
categories as occupational exposure increased and
across occupational categories as residential exposure
increased. This was true even when the exposure might
be intermittent, as in the case of indoor workers living
in high sunlight exposure areas.
The stronger negative association with sunlight
exposure among younger people further argues
against a positive causal role for sunlight exposure in
non›Hodgkin’s lymphoma. In younger people there is
less likely to be misclassification of exposure because
occupations and residences recorded at death are less
commonly succeeded by a retirement period or
preceded by a retirement move.
In support of the hypothesis that sunlight contrib›
utes to the incidence of non›Hodgkin’s lymphoma,
Adami cited the observed increased risk of non›
Hodgkin’s lymphoma in outdoor workers.21 Particular
outdoor occupations, including farming, forestry, and
fishing, have been associated with increased risk of
non›Hodgkin’s lymphoma.22 We examined the collec›
tive risk of about 40 outdoor jobs other than farming,
as well as farming, an occupational exposure that
potentially posed particular risks. Our results showed a
negative association for outdoor work generally
whereas, as expected, the odds ratio for farming was
raised.
Other findings in our study supported an
association between sunlight exposure and skin cancer
and melanoma but not non›Hodgkin’s lymphoma.
Both melanoma23 24 and skin cancer10 have been associ›
ated with fair skin. If sunlight plays a part in
non›Hodgkin’s lymphoma skin pigmentation may
similarly affect susceptibility. Thus the lower incidence
of non›Hodgkin’s lymphoma among African Ameri›
cans has been cited as supporting the sunlight›non›
Hodgkin’s lymphoma hypothesis.21 The reported lower
incidence in African Americans in the United States,
however, derives from cancer registry data and is not
adjusted for socioeconomic status.25 When we control›
led for socioeconomic status the risks in African
Americans exceeded those in people likely to have fair
pigmentation and other white subjects. Moreover,
there was no association between non›Hodgkin’s
lymphoma and residential sunlight exposure among
people with fair pigmentation. In contrast, residential
sunlight exposure was strongly associated with skin
cancer and melanoma in this group.
Assessing exposure
There were limitations in the assessments of exposure
in this study. Characterisation of residential sunlight
exposure is subject to many sources of potential
misclassification bias. Solar radiation contours were
based on data from weather stations that could not
measure all places and all conditions. The usual occu›
pation entered on a death certificate may reflect most
recent occupation, not a lifetime occupational history.
Furthermore, residential exposure was based on state
of residence at death, not lifetime residential history.
None the less, depending on the region, between about
70% and 80% of subjects were born in the same expo›
sure regions that they resided in at death. Moreover, to
the extent that such misclassifications are made
non›differentially the resulting bias is likely to dilute
associations. This suggests that the true association
with non›Hodgkin’s lymphoma could be a greater
deficit than observed here.
Socioeconomic and cultural differences
Socioeconomic status based on usual occupation at the
time of death also could not account for lifetime occu›
pational histories, education, or income. Yet the
associations observed with socioeconomic status
support the validity of the classification system.
Socioeconomic status as categorised in this model
showed a dose›response relation with the risk of
melanoma, which is consistent with the findings of sev›
eral studies.24 26 27 Socioeconomic status also seemed
related to non›Hodgkin’s lymphoma risk in our study,
an association noted in some but not all populations.25
We considered the possibility that cultural differ›
ences between states in the northern and southern lati›
tudes of the United States would increase the HIV
related non›Hodgkin’s lymphoma mortality in the
north and thus confound observed associations. That
we did not include death certificates from California,
New York, Florida, or Texas—four states with the high›
est percentage of AIDS cases28—limits substantially
potential confounding by HIV related non›Hodgkin’s
lymphoma mortality. Moreover, such confounding if
present would not seem to account for the negative
association between residential sunlight and non›
Hodgkin’s lymphoma in view of the fact that the nega›
tive association also characterised the subpopulations
of white men, white women, black men, black women,
young people, and old people.
The associations explored in this study between
sunlight indicators and non›Hodgkin’s lymphoma
were virtually all negative. That they did not resemble
the associations observed between sunlight and
melanoma, and particularly sunlight and non›
melanotic skin cancer, argues against sunlight as a
strong explanatory factor in the increased incidence of
non›Hodgkin’s lymphoma. This analysis cannot,
however, rule out a complex role for sunlight in the
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aetiology of non›Hodgkin’s lymphoma. There may, for
example, be unsuspected environmental agents that
are both correlated with northern latitudes of the
United States and potent causal agents for non›
Hodgkin’s lymphoma and which mask a positive but
weaker association with sunlight. It is possible that such
factors are correlated with different latitudes in
different countries, thus explaining the varied findings
of ecological studies of latitude and non›Hodgkin’s
lymphoma.7›9 Our finding that indoor work and
regions of low sunlight exposure increase, not
decrease, the risks of non›Hodgkin’s lymphoma needs
to be confirmed, and the elusive agent or agents
accounting for this increase need to be identified.
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Transfer of adults between intensive care units in the
United Kingdom: postal survey
Peter A Mackenzie, Elizabeth A Smith, Peter G M Wallace
In 1986, at least 10 000 seriously ill patients in the
United Kingdom required secondary transfer to adult
intensive care units in other hospitals.1 Although 75 of
181 (41%) intensive care consultants were dissatisfied
with transfer arrangements, only 10% (number not pro›
vided) ever refused a request for transfer. The establish›
ment of dedicated regional transport services was
recommended. It has also been recommended that
patientsshouldberetrievedbyteamsfromreceivinginten›
sive care units, and that local capabilities be maintained
for urgent transfer of patients with head injuries.2 3 We
reviewed current secondary transfer facilities and num›
bers and established the main indications for transfers.
Methods and results
Late in 1994 we surveyed 278 general or mixed inten›
sive care units in the United Kingdom by postal ques›
tionnaire; 198 (71%) responded. The mean annual
admission rate to intensive care units was 353 (range
Key messages
x The incidence of non›Hodgkin’s lymphoma has
risen rapidly in recent decades throughout
much of the world
x Several investigators have hypothesised that
increased exposure to sunlight may contribute
to this rising incidence
x A study in the United States found that sunlight
exposure based on residence and occupation
was not positively associated with
non›Hodgkin’s lymphoma
x The study found no evidence to support the
hypothesis that sunlight contributes to the rising
rates of non›Hodgkin’s lymphoma
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40›1540) patients, and annually an average of 23
patients were transported to each unit. The most
frequently quoted reasons (not mutually exclusive) for
such transfers were lack of intensive care beds (125;
63%) and of renal support services (45; 23%) in refer›
ring hospitals. Only 25 intensive care units admitted
more than 40 transferred patients a year.
On average, 19 patients were transported from
each unit each year. The most common indications for
these transfers were referral for neurosurgical care
(109; 55%), lack of beds in the intensive care unit (87;
44%), and lack of renal support services (54; 27%).
Only 12 intensive care units transferred more than 40
patients a year to another hospital.
Staff and equipment for transfers were available in
191 (97%) hospitals. The 24 (12%) intensive care units
which provided retrieval teams received on average 55
transferred patients a year. Only two hospitals
provided “regional” transport teams. Table 1 shows
equipment and staff resources. Eighty two (41%)
respondents considered that arrangements for transfer
were unsatisfactory. Despite this, only 19 (10%) stated
that lack of facilities ever prevented patient transfer.
Comment
On the basis of data from our survey and an audit of
admissions to a regional neurosurgical unit4 we
estimate that the number of critically ill patients
requiring secondary transport to adult intensive care
units in Britain in 1994 exceeded 11 000. This estimate
correlates well with that of the 1986 survey. Targeted
provision of staffed beds and renal support services in
existing general intensive care units would reduce the
number of transfers. Conversely, regionalisation of
specialist intensive care services may increase transfers
unless there are fewer hospitals with small intensive
care units and accident and emergency departments.
Most patients were transferred by staff from
referring hospitals. Most medical escorts were unsu›
pervised junior trainees in anaesthetics, each likely to
experience few transfers. Transportation by doctors
lacking suitable experience may result in a higher inci›
dence of life threatening complications,5 especially as
recommended monitoring is not universally available.2
Critically ill adults can be transferred safely by fully
equipped, specialised transfer teams; although these
are common in Australia, North America, and some
European countries, they remain the exception in the
United Kingdom.
The persistent professional dissatisfaction with
transfer arrangements probably reflects having to send
inadequately trained medical escorts and the need for
consultants to cover the emergency service in their
absence. Targeted allocation of resources is required to
reduce the number of transfers and provide a national
system for safe secondary transportation of critically ill
adults. A system of dedicated regional transport services
would result in most patients being transferred by well
equipped, experienced medical attendants and would
spare staff on call at referring and receiving hospitals.
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Chlamydia pneumoniae antibodies and serum lipids in
Finnish men: cross sectional study
Aino Laurila, Aini Bloigu, Simo Näyhä, Juhani Hassi, Maija Leinonen, Pekka Saikku
Chlamydia pneumoniae is an intracellular Gram negative
bacterium that commonly causes respiratory infec›
tions. C pneumoniae infection has been associated with
atherosclerosis in seroepidemiological studies, and the
organism was recently found within atherosclerotic
lesions.1 It is also known that acute infections interfere
with lipid metabolism. Raised concentrations of
triglycerides have been detected in Gram negative
infections, and concentrations of high density lipopro›
tein cholesterol have been shown to decrease in both
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Table 1 Resources available at adult intensive care units for
transfer of critically ill patients. Values are numbers
(percentages)
Resources
1994
(n=198)
1986
(n=181*)
Staff:
Escorted by senior house officer or registrar 175 (88)
Escorted by anaesthetic staff 193 (97) 166 (92)
Non›anaesthetic medical escort 2 (1) 88 (49)
Escorted by on call staff 180 (91)
Additional nurse escort 190 (96) 166 (92)
Equipment or monitoring:
Dedicated ambulance 43 (22) 64 (35)
Dedicated trolley 41 (21) 38 (21)
Ventilator 188 (95) 129 (71)
Defibrillator 183 (92) 146 (81)
Electrocardiograph 195 (98) 165 (91)
Box of transfer drug† 195 (98) 164 (91)
Pulse oximetry 197 (99)
Non›invasive blood pressure 187 (94)
Invasive blood pressure 163 (82)
Central venous or pulmonary artery pressure 126 (64)
End tidal carbon dioxide 48 (24)
Battery powered infusion devices 198 (100)
*A 64% response rate.1
†For intubation, anaesthesia, and cardiovascular resuscitation.
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bacterial and viral infections.2 We studied the effect of C
pneumoniae infection on serum lipid concentrations.
Methods and results
The study population consisted of 1053 men who par›
ticipated in a reindeer herders’ health survey
performed in Finland 1986›9.3 Blood samples were
taken after 12 hours of fasting. Total cholesterol, high
density lipoprotein cholesterol, and triglyceride con›
centrations were measured by routine enzymatic
methods. Serum IgG and IgA antibodies specific for C
pneumoniae antibodies were determined by the
microimmunofluorescence method using C pneumo›
niae strain Kajaani 6 as an antigen. Analysis of
covariance with age as a covariate was used to test con›
centrations of serum triglyceride, total cholesterol, and
high density lipoprotein and ratios of high density
lipoprotein cholesterol to total cholesterol in groups
classified by smoking and antibodies specific to C pneu›
moniae.
The mean age of the study group was 47 (range 20
to 87) years; 32% (337) were current smokers. Both
antibody prevalence and the age adjusted geometric
mean antibody titres were significantly higher in smok›
ers than in non›smokers; IgG antibodies were present
(titre >32) in 83% (280/337) of smokers and in 77%
(417/542) of non›smokers (P < 0.01). Overall the geo›
metric mean triglyceride concentration was 1.14
(range 0.32›9.07) mmol/l, the mean total cholesterol
concentration 6.4 (3.1›11.2) mmol/l, and the mean
high density lipoprotein cholesterol concentration
1.26 (0.56›3.11) mmol/l. The geometric mean ratio of
high density lipoprotein cholesterol to total cholesterol
was 0.19 (0.07›0.72). Triglyceride and total cholesterol
concentrations were higher and high density lipopro›
tein cholesterol concentrations lower in smokers than
in non›smokers. Table 1 shows age adjusted geometric
means and ratios according to C pneumoniae specific
IgG antibody titres and smoking. In non›smokers, trig›
lyceride concentrations increased and high density
lipoprotein cholesterol concentrations and high
density lipoprotein cholesterol:total cholesterol ratios
decreased significantly (P = 0.017, 0.001, and 0.001,
respectively) according to IgG antibody titres; values
did not differ significantly in smokers. Overall, subjects
positive for IgG had significantly higher triglyceride
concentrations and lower high density lipoprotein
cholesterol concentration and the high density
lipoprotein cholesterol:total cholesterol ratios
(P = 0.06, 0.003, and 0.007, respectively). Presence of
IgA antibodies (titre>16) had only a minor association
with lipid concentrations.
Comment
Changes in lipid metabolism are well recognised in the
pathogenesis of atherosclerosis. High concentrations
of triglycerides and low concentrations of high density
lipoprotein cholesterol, as well as low ratios of high
density lipoprotein cholesterol:total cholesterol, are
known to be important risk factors for coronary heart
disease.
The specific IgG antibodies in these men suggest
that they have been infected by C pneumoniae or have a
persistent C pneumoniae infection; the altered serum
lipid values may thus reflect disturbances in lipid
metabolism caused by infection. As a Gram negative
bacterium, C pneumoniae contains lipopolysaccharide
as a major constituent of its outer membrane. It can
multiply in macrophages, smooth muscle, and
endothelial cells and induce production of tumor
necrosis factor and interleukin›1.1 In macrophages and
smooth muscle cells in atherosclerotic lesions C
pneumoniae and its lipopolysaccharide may lead to
continuous production of cytokines and thus to an
altered serum lipid profile. Several other chronic
bacterial infections such as Helicobacter pylori infection
have recently been connected to atherosclerosis.4 If
these infections contribute even partly to the altered
serum lipid profile, eradication of the infection by anti›
biotic treatment would decrease the risk of atheroscle›
rotic disease.
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Table 1 Serum triglyceride, total cholesterol, high density lipoprotein cholesterol concentrations (mmol/l) and ratio of high density
lipoprotein cholesterol to total cholesterol in Finnish men according to C pneumoniae specific IgG antibody titres and smoking,
adjusted for age
Smokers† (n=506) Non›smokers (n=542) Total‡ (n=1053)
IgG
<32
IgG
32›128
IgG
>128
IgG
<32
IgG
32›128
IgG
>128
IgG
<32
IgG
32›128
IgG
>128
Triglyceride concentration
(mmol/l; geometric mean)
1.18 1.17 1.18 1.00 1.12 1.14* 1.06 1.15 1.16
Total cholesterol concentration
(mmol/l; mean)
6.51 6.46 6.47 6.25 6.32 6.33 6.36 6.38 6.41
HDL cholesterol concentration
(mmol/l; mean)
1.27 1.25 1.24 1.36 1.23 1.24** 1.32 1.24 1.24**
Ratio of HDL to total cholesterol
(geometric mean)
0.19 0.19 0.19 0.22 0.19 0.19** 0.21 0.19 0.19**
*P<0.05; **P<0.01 from analysis of covariance, adjusted for age.
†Includes occasional smokers and former smokers.
‡Data on smoking missing for 5 subjects.
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